2 weeks Ago By ABMN Staff
CreativeOne Wealth LLC purchased a new position in Illumina, Inc. ( NASDAQ:ILMN – Free Report ) during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 1,853 shares of the life sciences company’s stock, valued at approximately $248,000.
Other institutional investors also recently bought and sold shares of the company. Bank of Stockton increased its stake in shares of Illumina by 3.8% in the fourth quarter.
Bank of Stockton now owns 2,162 shares of the life sciences company’s stock worth $289,000 after acquiring an additional 80 shares during the period. Stephens Inc. AR boosted its holdings in Illumina by 1.
4% in the fourth quarter. Stephens Inc. AR now owns 6,623 shares of the life sciences company’s stock valued at $885,000 after purchasing an additional 90 shares during the last quarter.
Spire Wealth Management grew its position in Illumina by 26.0% during the 4th quarter. Spire Wealth Management now owns 470 shares of the life sciences company’s stock worth $63,000 after purchasing an additional 97 shares during the period.
IFP Advisors Inc lifted its holdings in shares of Illumina by 19.1% in the 4th quarter. IFP Advisors Inc now owns 617 shares of the life sciences company’s stock valued at $82,000 after buying an additional 99 shares during the period.
Finally, Brooklyn Investment Group grew its holdings in Illumina by 20.5% during the fourth quarter. Brooklyn Investment Group now owns 611 shares of the life sciences company’s stock worth $82,000 after acquiring an additional 104 shares during the period.
89.42% of the stock is owned by hedge funds and other institutional investors. Analyst Upgrades and Downgrades ILMN has been the topic of a number of recent analyst reports.
Barclays lowered their price target on shares of Illumina from $100.00 to $77.00 and set an “underweight” rating on the stock in a report on Thursday, April 10th.
Hsbc Global Res lowered shares of Illumina from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 28th. HSBC downgraded shares of Illumina from a “buy” rating to a “hold” rating and set a $100.00 price objective for the company.
in a report on Friday, February 28th. Morgan Stanley lowered their target price on Illumina from $150.00 to $136.
00 and set an “equal weight” rating on the stock in a report on Tuesday, February 11th. Finally, Robert W. Baird cut their price target on Illumina from $127.
00 to $90.00 and set a “neutral” rating for the company in a report on Wednesday, March 5th. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock.
According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $138.70.
Illumina Price Performance ILMN stock opened at $71.21 on Monday. The business’s fifty day moving average price is $84.
61 and its 200 day moving average price is $120.16. Illumina, Inc.
has a 12-month low of $68.70 and a 12-month high of $156.66.
The company has a market capitalization of $11.27 billion, a PE ratio of -9.27, a P/E/G ratio of 1.
60 and a beta of 1.38. The company has a current ratio of 1.
77, a quick ratio of 1.42 and a debt-to-equity ratio of 0.63.
Illumina ( NASDAQ:ILMN – Get Free Report ) last posted its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing the consensus estimate of $0.
92 by ($0.06). Illumina had a negative net margin of 27.
95% and a positive return on equity of 13.37%. On average, sell-side analysts anticipate that Illumina, Inc.
will post 4.51 EPS for the current year. Illumina Profile ( Free Report ) Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally.
It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. Featured Articles Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Illumina, Inc. ( NASDAQ:ILMN – Free Report ). Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.
com's FREE daily email newsletter ..
